VETAMEG- flunixin meglumine paste
Aspen Veterinary Resources
ANADA 200-581, Approved by FDA
VetaMeg® Equine Paste
SYRINGE CONTAINS FLUNIXIN MEGLUMINE EQUIVALENT TO 1500 mg FLUNIXIN
FOR ORAL USE IN HORSES ONLY
KEEP OUT OF REACH OF CHILDREN
WARNING: Do not use in horses intended for human consumption.
ACTIVITY: Flunixing meglumine is a potent, nonnarcotic, nonsteroidalm analgesic agent with anti-inflammatory and antipyretic activity, It is significantly more potent than pentazocine, meperidine, and codeine as an analgensic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs withing 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.
CONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.
PRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.
SIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.
DOSAGE AND ADMINISTRATION: The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The VetaMeg® Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.
|Syringe Mark*||Horse Weight (lbs)||VetaMeg™ Equine Paste Delevered (g)||mg Flunixin Delivered|
* Use dial edge nearest syringe barrel to mark dose.
The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.
Treatment may be given initially by intravenous or intramuscular injection of VetaMeg™ Injectable Solution, followed by VetaMeg™ Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.
TOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.
WARNING: D o not use in horses intended for human consumption.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
INDICATIONS: For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.
DOSE: 0.5 mg per pound of body weight per day for up to 5 days. Each calibration on the syringe’ doses 250 lbs of body weight. Administer orally by inserting the nozzle of the syringe through the interdental space and depositing the required amount of paste on the back of the tongue by depressing the plunger. *Use dial edge nearest syringe barrel to mark dose.
STORAGE: Store at 20°C — 25°C (68°F — 77°F); excursions permitted between 15°C — 30°C (between 59°F — 86°F)
See product information sheet for additional information.
| VETAMEG |
flunixin meglumine paste
|Labeler — Aspen Veterinary Resources (627265361)|
|Registrant — Bimeda Inc. (060492923)|
Revised: 02/2021 Aspen Veterinary Resources
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.